Kumar Neil 4

What Happened Neil Kumar, CEO of BridgeBio Pharma, sold a total of 28,053 shares in open-market transactions on February 19, 2026, generating roughly $2,002,718 in proceeds. The sales were: 18,923 shares at $71.03 ($1,344,190); 8,528 shares at $72.08 ($614,702); and 602 shares at $72.80 ($43,826). These were dispositions (sales), not purchases.

Key Details

• Transaction date: February 19, 2026 (reported on Form 4 filed February 23, 2026). Filing appears timely under Section 16 rules.
• Prices and values: 18,923 @ $71.03; 8,528 @ $72.08; 602 @ $72.80 — total proceeds ≈ $2,002,718.
• Total shares sold: 28,053.
• Shares owned after transaction: Not specified in the provided filing disclosure.
• Notable footnotes:
  • Sale effected pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025.
  • Footnotes list weighted-average price ranges for the sales and offer to provide per-price detail to the SEC, issuer, or shareholders on request.
  • Reporting person disclaims beneficial ownership except to extent of pecuniary interest (standard disclaimer in filing).

Context

• These were routine sales under a pre-established 10b5-1 plan, which typically allows insiders to sell shares at pre-set times regardless of current company news. Sales are not, by themselves, evidence of the insider’s view on the company’s prospects.